In This Section

Research Funding Impact

Since 1993, the AACR has awarded more than $540 million in grants to fund meritorious research projects across the spectrum of cancer science, including basic, translational, and clinical research. See how the AACR grants program has contributed to the AACR's mission.

Search/Filter
Category
AACR Career Development AwardsAACR Research GrantsGrantee ImpactGrantee NewsGrantee StoryGrants News
Loading...
Impacting community through community: AACR-Genentech Cancer Disparities Fellow provides a window into Latino smokers’ perceptions on physical activity and the importance of community engagement

Impacting community through community: AACR-Genentech Cancer Disparities Fellow provides a window into Latino smokers’ perceptions on physical activity and the importance of community engagement

A growing share of US adult smokers – Hispanic/Latino adults – have been found to be less likely to receive advice to quit and use proven cessation treatments than non-Hispanic white adults. 2021 AACR-Genentech Cancer Disparities Fellow Francisco Cartujano, MD, seeks to address tobacco-related disparities in Latinos by promoting smoking cessation and physical activity using a mobile intervention.

Category: Grantee Impact
Learn More
AACR-Bayer Innovation and Discovery Grantee Designs an MDM2-Targeted PROTAC to Treat Triple Negative Breast Cancer

AACR-Bayer Innovation and Discovery Grantee Designs an MDM2-Targeted PROTAC to Treat Triple Negative Breast Cancer

Triple negative breast cancer (TNBC) is an aggressive cancer with high rates of p53 inactivation and lower survival rates than other breast cancer types due to increased metastasis and relapse (1). Owing to the frequent inactivation of p53, compounds that inhibit p53 from binding to its negative regulator, MDM2, are ineffective in TNBC. In a recent study published in Cancer Discovery, Dr. Eischen and her colleagues used an MDM2-targeted PROteolysis TArgeting Chimera (PROTAC) to reveal the requirement for MDM2 in p53 inactivated TNBC and identify a new therapeutic target for the disease.

Category: Grantee Impact
Learn More
Meet the Research Grant Reviewer Session Provides an Opportunity to Interact with AACR Grant Reviewers at AACR Annual Meeting 2023

Meet the Research Grant Reviewer Session Provides an Opportunity to Interact with AACR Grant Reviewers at AACR Annual Meeting 2023

Please join us for an interactive session taking place Monday, April 17th, at the AACR Annual Meeting 2023. The Meet the Research Grant Reviewers session, will give you an opportunity to ask AACR grant reviewers, Dr. DeGregori and Dr. Iacobuzio-Donahue, any questions you may have. We offer you a sneak peak of what you can learn from attending the session here!

Category: Grantee News
Learn More
AACR Grantees Present Their Work at the AACR Annual Meeting 2023

AACR Grantees Present Their Work at the AACR Annual Meeting 2023

Between April 14 – 19, the 2023 AACR Annual Meeting will welcome the best cancer scientists from all over the world to the Orange County Convention Center, Orlando, Florida. We are excited to announce the AACR grantees selected to present their work in oral and poster presentations. We are extremely proud and excited to hear of the progress they have made with support from the AACR and its funding partners!

Category: Grantee News
Learn More
AACR-PanCAN Pathway to Leadership Grant Helps Launch Scientists’ Independent Careers in Pancreatic Cancer Research

AACR-PanCAN Pathway to Leadership Grant Helps Launch Scientists’ Independent Careers in Pancreatic Cancer Research

Dedicated to accelerating the conquest of cancer, the AACR is a unique organization committed to funding research projects across all cancer sites and researchers at all career levels. In partnership with the Pancreatic Cancer Action Network (PanCAN), a nationwide organization dedicated to pancreatic cancer, the AACR-PanCAN Pathway to Leadership Grant was established in 2010. Running until 2017, the joint program offered $600,000 over five years to facilitate the career transition of pancreatic cancer researchers from postdoctoral/clinical research fellow to independent faculty.

Category: Grants News
Learn More
AACR-Novocure grantee elucidates the impact of Tumor Treating Fields on the blood-brain barrier

AACR-Novocure grantee elucidates the impact of Tumor Treating Fields on the blood-brain barrier

Treatment options for brain cancers, including aggressive glioblastoma, are limited despite the availability of several chemotherapeutic drugs due to the inability of these drugs to cross the blood-brain barrier (BBB). AACR-Novocure grantee Dr. Carsten Hagemann and his team showed that the use of low-intensity alternating electric fields known as Tumor Treating Fields (TTFields), an FDA-approved treatment modality, can facilitate drugs crossing the BBB. Using multiple models, they elucidated the mechanisms driving this action.

Category: Grantee Impact
Learn More